ACRIS COMBI

Active ingredients

The drug ACRIS COMBI contains a combination of these active pharmaceutical ingredients (APIs):

UNII OFG5EXG60L - RISEDRONATE SODIUM

Risedronic acid is a pyridinyl bisphosphonate that binds to bone hydroxyapatite and inhibits osteoclast-mediated bone resorption. The bone turnover is reduced while the osteoblast activity and bone mineralisation is preserved.

Read about Risedronic acid
UNII H0G9379FGK - CALCIUM CARBONATE

Calcium carbonate releases, in a pH-dependent manner, calcium ions in the stomach. Calcium carbonate is widely used as antacid and extensively used as a dietary supplement.

Read about Calcium carbonate

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
M05BB02
Risedronic acid and calcium, sequential
M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BB Bisphosphonates, combinations
Discover more medicines within M05BB02

Authorization and marketing

This brand name is authorized in the following countries: Australia

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
AU
Pharmaceutical Benefits Scheme
Identifier(s): 4059P, 8899J